Vaccines

A multisite surveillance study published in Pediatrics assessed trends and determinants of influenza antiviral use in hospitalized children across the United States before and during the late COVID-19...

A systematic review of 155 studies found COVID-19 vaccines reduced severe outcomes across age and risk groups without new safety signals.

A prespecified DAN-RSV trial analysis found RSVpreF reduced RSV-related hospitalization regardless of heart failure status.

August 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a...

Dr. William Schaffner, MD, reviews evolving adult vaccination guidance and key opportunities to prevent severe disease in clinical practice.

A randomized trial evaluated whether the 4CMenB vaccine prevents gonorrhea among adults at high risk for infection.

The FDA approved an mRNA-based influenza vaccine mFLUSIVA for adults aged 50 years and older, with accelerated approval applying to adults aged 65 years and older.

New influenza and RSV research offers clinically relevant insights into vaccine performance and outbreak prevention. This roundup examines an investigational mRNA flu vaccine, rapid oseltamivir use in...

A real-world analysis found that mRNA SARS-CoV-2 vaccination was associated with lower 3-year mortality after CAR T-cell therapy in patients with hematologic malignancies.

Recent studies address Long COVID surveillance, household transmission, updated vaccine effectiveness, kidney outcomes, and influenza vaccine coadministration.